Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 85-100

  Lee, Lydia ^b   Fielding, Adele K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

Acute lymphoblastic leukemia; Developments; Therapy

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; AURORA KINASE INHIBITOR; BLINATUMOMAB; CLOFARABINE; COMBOTOX; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FORODESINE; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MITOXANTRONE; MK 0752; NELARABINE; NOTCH 1 INHIBITOR; NOTCH1 RECEPTOR; PROTEIN INHIBITOR; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; SORAFENIB; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE; XL 228;

ABNORMAL LABORATORY RESULT; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APLASIA; APOPTOSIS; ATAXIA; BLOOD TOXICITY; BRAIN DISEASE; BURKITT LYMPHOMA; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFUSION; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HUMAN; INFECTION; INSULIN BLOOD LEVEL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOENCEPHALOPATHY; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOBLASTOMA; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCYTOPENIA; POLYOMAVIRUS INFECTION; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS HEPATITIS; WEAKNESS;

EID: 84857012512     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7262     Document Type: Review

References (113)

1. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. Dec 1, 2005;106(12):3760-7.
2. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. Nov 15, 2004;104(10):3028-37.
3. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. May 15, 2002;20(10):2464-71.
4. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. February 1, 2002;99(3):863-71.
5. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. Feb 2001;15(2):208-16.
6. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper- CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. Feb 2000;18(3):547-61.
7. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. Dec 2000;14(6):1307-25, ix.
8. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. February 12, 2009;113(7):1408-11.
9. Fielding A. The treatment of adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2008:381-9.
10. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. Mar 22, 2008;371(9617):1030-43.
11. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. Jul 30, 2010;70(11):1445-76.
12. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. Jul 1, 2006;24(19):3121-7.
13. Dworzak MN, Fritsch G, Fleischer C, et al. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia- associated aberrations. Exp Hematol. Apr 1998;26(4):305-13.
14. Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. Nov 15, 2008;112(10):3982-8.
15. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper- CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. Apr 1, 2006;106(7): 1569-80.
16. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab in adult CD20+ B-Precursor ALL improves molecular CR rate and outcome in standard risk as well as in high risk patients with stem cell transplant. Haematologica. 2009;94(Suppl 2):Abst 481.
17. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. Aug 20, 2010;28(24):3880-9.
18. Hoelzer D, Goekbuget N, Beck J, et al. Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL). 46th Annual Meeting American Society of Haematology, San Diego, U S A. Blood. 2004;104(11):abstract 2732.
19. Thomas DA, Kantarjian H, Cortes J, et al. Long-Term Outcome after Hyper- CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt- Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL). 49th Annual Meeting American Society of Hematology, Atlanta, U S A. Blood. 2007;110(11):abstract 2825.
20. Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. Feb 2010;95(2): 324-8.
21. Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. Jun 18, 2009;113(25):6330-7.
22. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2002:162-92.
23. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. Feb 1, 2011;25(1):13-25.
24. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. Aug 1, 2008;26(22):3756-62.
25. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. Aug 1, 2008;68(15):6300-5.
26. Schindler J, Gajavelli S, Ravandi F, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol. July 7, 2011:epub ahead of print July 7.
27. Herrera L, Bostrom B, Gore L, et al. A phase 1study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol. Dec 2009;31(12):936-41.
28. Jabbour E, O'Brien S, Thomas D, et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). J Clin Oncol. 2011;29(Suppl):6507.
29. Kebriaei P, Wilhelm K, Ravandi F, et al. Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL). 53rd Annual Meeting American Society of Hematology, San Diego, U S A. Blood. 2011;118(21):abstract 3102.
30. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell- engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Jun 20, 2011;29(18):2493-8.
31. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. August 15, 2008; 321(5891):974-7.
32. ® Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: Interim Results of a Phase 2 Study. Haematologica. June 1, 2011;96(Supplement 2: 16th Congress of European Hematology Association, London, United Kingdom): Abstract 552.
33. Topp M, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial. 53rd Annual Meeting American Society of Hematology, San Diego, U S A. Blood. 2011;118(21):Abstract 252.
34. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem. 2006;13(26):3165-89.
35. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. May 20, 2005;23(15):3396-03.
36. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. Jun 15, 2007;109(12):5136-42.
37. Goy A BA, Hagemeister F, et al. Phase II study of compound GW506U78 (araG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy. 45th Annual Meeting American Society of Hematology; San Diego, U S A. 2003:Abstract 2359.
38. Czuczman MS, Porcu P, Johnson J, et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. Jan 2007;48(1):97-103.
39. Gokbuget N, Basara N, Baurmann H, et al. High single drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. June 28, 2011:epub ahead of print Jun 28.
40. Rodriguez CO Jr, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. Oct 1, 1999;59(19):4937-43.
41. Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. Aug 2010;150(3):345-351.
42. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. Mar 15, 2003;21(6):1167-73.
43. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. Oct 1, 2003;102(7):2379-86.
44. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. Feb 1, 2005;105(3):940-7.
45. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. Sep 15, 2007;110(6):1762-9.
46. Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. Dec 2010;151(5):430-4.
47. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy- 2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res. May 1, 1991;51(9):2386-94.
48. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. Nov 15, 2000;96(10):3537-43.
49. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. Feb 1, 2004;103(3):784-9.
50. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. Apr 20, 2006;24(12):1917-23.
51. O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol. Aug 2011;154(4):482-5.
52. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. Nov 2001;7(11):3580-9.
53. Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. Apr 2005;55(4):361-8.
54. Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL. One- third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. Jun 16, 1998;37(24):8615-21.
55. Homminga I, Zwaan CM, Manz CY, et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood. Aug 25, 2011;118(8): 2184-90.
56. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A. Apr 10, 2001;98(8): 4593-8.
57. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX- 1777. Int Immunopharmacol. Jun 2003;3(6):879-87.
58. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. Dec 15, 2005;106(13):4253-60.
59. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009:353-61.
60. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. Aug 23, 1991;66(4):649-61.
61. Palomero T, Barnes KC, Real PJ, et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia. Jul 2006; 20(7):1279-87.
62. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. Oct 8, 2004; 306(5694):269-71.
63. Deangelo D, Stone R, Silverman L, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/ lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology, ASCO Annual Meeting Proceeding. 2006;(Jun 20 Supplement):No. 18S: 6585.
64. Lewis HD, Leveridge M, Strack PR, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol. Feb 2007;14(2):209-19.
65. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. Oct 2007; 13(10):1203-10.
66. Okuhashi Y, Itoh M, Nara N, Tohda S. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res. Mar 2011;31(3):893-6.
67. Rao SS, O'Neil J, Liberator CD, et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. Apr 1, 2009; 69(7):3060-8.
68. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. Jul 1, 2007;110(1):278-6.
69. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. Jan 2009;15(1):50-8.
70. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. Jun 2009;145(5):569-80.
71. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. May 1, 2008;14(9):2756-2762.
72. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. Sep 1, 2006;12(17):5165-73.
73. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica. Jan 2011;96(1):69-77.
74. Teachey DT, Sheen C, Hall J, et al. Mtor inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. Sep 1, 2008;112(5):2020-3.
75. Gu L, Zhou C, Liu H, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res. 2010;29:150.
76. Batista A, Barata JT, Raderschall E, et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. Apr 2011;39(4):457-72 e453.
77. Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res. 2008;42(1-3):84-105.
78. Breslin EM, White PC, Shore AM, Clement M, Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol. Mar 2005;144(6):791-800.
79. Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3 K blocks BCRABL leukemogenesis in mice, and a dual PI3 K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. Sep 2008; 118(9):3038-50.
80. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. Oct 1, 2004;64(19):7099-109.
81. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. Oct 20, 2005;24(46):6861-9.
82. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. Mar 2007;21(3):439-45.
83. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. Feb 6, 2008;100(3):184-98.
84. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. Jan 2011;96(1):62-8.
85. Schult C, Dahlhaus M, Ruck S, et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer. 2010; 10:560.
86. Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. Aug 2010; 24(8):1437-44.
87. Ikezoe T, Nishioka C, Tasaka T, et al. ZM447439, a Novel Aurora Kinase Inhibitor, Induces Growth Arrest and Apoptosis of Human Leukemia Cells. 48th Annual Meeting American Society of Hematology, Orlando, U S A. Blood. 2006;108(11):abstract 1990.
88. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. Jun 28, 2007;251(2): 323-9.
89. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. Jan 15, 2007;109(2):500-2.
90. Pharmaceuticals V. Vertex's collaborator Merck suspends patient enrollment in clinical trials of MK-0457 (VX-680) pending full analysis of clinical data. http://investors.vrtx.com/releasedetail.cfm?releaseid276543. 2007.
91. Foran JM, Ravandi F, O'Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2008:Abstract 2518.
92. Cortes J, Paquette R, Talpaz M, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. 50th Annual Meeting American Society of Hematology, San Francisco, U S A. Blood. 2008;112(11):abstract 3232.
93. Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. 51st Annual Meeting American Society of Hematology, New Orleans, U S A. Blood. 2009;114(22):abstract 864.
94. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. Sep 15, 2007;110(6): 2034-40.
95. Fei F, Stoddart S, Muschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. Apr 2010;24(4):813-20.
96. Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol. Nov 2010;89(11):1081-7.
97. Nguyen T, Dai Y, Attkisson E, et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. May 15, 2011;17(10):3219-32.
98. Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia- positive leukemias. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Apr 2010;24(4): 671-8.
99. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. Feb 23, 2007;128(4):635-8.
100. Jones PA, Baylin SB. The epigenomics of cancer. Cell. Feb 23, 2007; 128(4):683-92.
101. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol. Jan 2009; 46(1):24-32.
102. Kuang SQ, Tong WG, Yang H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. Aug 2008;22(8):1529-38.
103. Krivtsov AV, Feng Z, Lemieux ME, et al. H3 K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. Nov 4, 2008;14(5): 355-68.
104. Birke M, Schreiner S, Garcia-Cuellar MP, Mahr K, Titgemeyer F, Slany RK. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res. Feb 15, 2002;30(4):958-65.
105. Mummery A, Narendran A, Lee KY. Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia. Curr Cancer Drug Targets. Jul 15, 2011;11:882-93.
106. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. Aug 1, 2006;12(15):4628-35.
107. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. Feb 1, 2008;111(3):1060-6.
108. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. Aug 15, 2006;108(4):1174-82.
109. Schafer E, Irizarry R, Negi S, et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. Jun 10, 2010;115(23):4798-809.
110. Garcia-Manero G, Thomas DA, Rytting ME, et al. Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL). 52nd Annual Meeting American Society of Hematology, Orlando, U S A. Blood. 2010;116(21):abstract 867.
111. Hongo T, Fujii Y. In vitro chemosensitivity of lymphoblasts at relapse in childhood leukemia using the MTT assay. Int J Hematol. Jun 1991;54(3): 219-30.
112. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. Jan 2005;139(1):152-8.
113. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. Dec 11, 2010;376(9757):2009-17.